Product Description
Florbetaben (18F) is a stilbene derivative labeled with the positron-emitting isotope fluorine F 18, that may be used for positron emission tomography (PET) detection of beta-amyloid neuritic plaques and other amyloid protein deposits. Upon administration, F 18-florbetaben exhibits differential retention in regions that contain certain amyloid deposits. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Florbetaben-F-18)
Mechanisms of Action: APP Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Canada | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Korea | Latvia | Lithuania | Netherlands | Poland | Portugal | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States
Approved Indications: Alzheimer Disease | Dementia
Known Adverse Events: Pain Unspecified | Erythema
Company: Life Molecular Imaging
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Japan, Spain, United Kingdom, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Alzheimer Disease|Amyloidosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FBB-02-01-21a | P3 |
Unknown Status |
Amyloidosis |
2025-05-30 |
|
| CArdiag | P3 |
Recruiting |
Amyloidosis |
2025-03-01 |
86% |
| JapicCTI-101132 | P3 |
Active |
Alzheimer Disease |
2014-04-01 |